Back to Results

Brainstorm Cell Therapeutics Inc (BCLI)

Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing autologous cell therapies for neurodegenerative diseases. Its NurOwn platform is designed to use bone marrow-derived mesenchymal stem cells to produce neurotrophic factors, influence neuroinflammatory and neurodegenerative processes, support neuronal survival, and help improve neurological function. The company is advancing NurOwn across several disease areas, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer’s disease, and other neurodegenerative conditions. Incorporated in 2000, Brainstorm Cell Therapeutics is headquartered in New York, New York, and its common stock is listed on OTC Markets under the symbol BCLI.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BCLI
$0.98
3.5% Upside
Fair
$17 1,689.5% Upside
—
Bargain
Fair
—
—
—
0.0%
August 17, 2026
-1.1x
-1.0x
—
10.483 M
11.956 M
12.4%
89.9%
-500.1
—
69.6%
Send a message
Valuation • Fair Value

Brainstorm Cell Therapeutics Inc (OTC-BCLI) Fair Value by Valuation Model

Compare the primary fair value estimate for Brainstorm Cell Therapeutics Inc (OTC-BCLI) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.98

Estimated upside of 3.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.98

Comparable-company valuation reference.

Analyst Price Target

$17 1,689.5% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Brainstorm Cell Therapeutics Inc (OTC-BCLI) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Brainstorm Cell Therapeutics Inc (OTC-BCLI)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-8.726 M

Current operating profitability reference.

EBITDA Forecast

-23 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Brainstorm Cell Therapeutics Inc (OTC-BCLI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Brainstorm Cell Therapeutics Inc (OTC-BCLI)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-500.1

Lower score that deserves closer risk review.

FCF / Net Income

69.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Brainstorm Cell Therapeutics Inc (OTC-BCLI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Brainstorm Cell Therapeutics Inc (OTC-BCLI)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 17, 2026

Days to Earnings

27

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Brainstorm Cell Therapeutics Inc (OTC-BCLI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Brainstorm Cell Therapeutics Inc (OTC-BCLI) Stock Forecast & Technical Outlook

Review Brainstorm Cell Therapeutics Inc (OTC-BCLI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Brainstorm Cell Therapeutics Inc (OTC-BCLI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Brainstorm Cell Therapeutics Inc (OTC-BCLI) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Brainstorm Cell Therapeutics Inc (OTC-BCLI) Stock FAQ

Quick answers about Brainstorm Cell Therapeutics Inc (OTC-BCLI) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.98
Estimated upside 3.5%
Valuation Rating
Undervalued
Estimated upside of 3.5%
Analyst Target
$17 1,689.5% Upside
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is $0.98. This implies an estimated upside of 3.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.5% versus the current market price.

The available analyst price target for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is $17 1,689.5% Upside.

The current financial health read for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is August 17, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Brainstorm Cell Therapeutics Inc (OTC-BCLI) is -1.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Brainstorm Cell Therapeutics Inc is 10.483 M.

The current enterprise value listed for Brainstorm Cell Therapeutics Inc is 11.956 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Brainstorm Cell Therapeutics Inc is OTC-BCLI, and the stock is listed on OTC Markets.

Brainstorm Cell Therapeutics Inc (OTC-BCLI) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Brainstorm Cell Therapeutics Inc is 12.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Brainstorm Cell Therapeutics Inc is 89.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)